Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
VICL's Cash to Debt is ranked higher than
88% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. VICL: No Debt )
VICL' s 10-Year Cash to Debt Range
Min: 1.11   Max: No Debt
Current: No Debt

Equity to Asset 0.92
VICL's Equity to Asset is ranked higher than
95% of the 766 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. VICL: 0.92 )
VICL' s 10-Year Equity to Asset Range
Min: 0.8   Max: 0.97
Current: 0.92

0.8
0.97
Interest Coverage No Debt
VICL's Interest Coverage is ranked higher than
82% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. VICL: No Debt )
VICL' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 6
Z-Score: 4.09
M-Score: -2.04
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -169.67
VICL's Operating margin (%) is ranked higher than
65% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. VICL: -169.67 )
VICL' s 10-Year Operating margin (%) Range
Min: -730.44   Max: -26.06
Current: -169.67

-730.44
-26.06
Net-margin (%) -168.13
VICL's Net-margin (%) is ranked higher than
66% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -70.66 vs. VICL: -168.13 )
VICL' s 10-Year Net-margin (%) Range
Min: -651.2   Max: -24.26
Current: -168.13

-651.2
-24.26
ROE (%) -34.50
VICL's ROE (%) is ranked higher than
68% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. VICL: -34.50 )
VICL' s 10-Year ROE (%) Range
Min: -75.9   Max: -5.65
Current: -34.5

-75.9
-5.65
ROA (%) -31.77
VICL's ROA (%) is ranked higher than
66% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. VICL: -31.77 )
VICL' s 10-Year ROA (%) Range
Min: -62.48   Max: -5.23
Current: -31.77

-62.48
-5.23
ROC (Joel Greenblatt) (%) -281.50
VICL's ROC (Joel Greenblatt) (%) is ranked higher than
71% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. VICL: -281.50 )
VICL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -639.85   Max: -12.33
Current: -281.5

-639.85
-12.33
Revenue Growth (%) -13.70
VICL's Revenue Growth (%) is ranked higher than
69% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. VICL: -13.70 )
VICL' s 10-Year Revenue Growth (%) Range
Min: -39.7   Max: 28.1
Current: -13.7

-39.7
28.1
EBITDA Growth (%) -10.20
VICL's EBITDA Growth (%) is ranked higher than
73% of the 626 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. VICL: -10.20 )
VICL' s 10-Year EBITDA Growth (%) Range
Min: -54.7   Max: 42.3
Current: -10.2

-54.7
42.3
EPS Growth (%) -11.00
VICL's EPS Growth (%) is ranked higher than
75% of the 645 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. VICL: -11.00 )
VICL' s 10-Year EPS Growth (%) Range
Min: -52.4   Max: 50.2
Current: -11

-52.4
50.2
» VICL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

VICL Guru Trades in Q3 2013

Paul Tudor Jones 355,000 sh (New)
Jim Simons 212,100 sh (New)
Murray Stahl 84,500 sh (unchged)
John Rogers 5,069,238 sh (-1.28%)
» More
Q4 2013

VICL Guru Trades in Q4 2013

Jim Simons 338,204 sh (+59.45%)
John Rogers 7,062,104 sh (+39.31%)
Murray Stahl 84,500 sh (unchged)
Paul Tudor Jones 105,500 sh (-70.28%)
» More
Q1 2014

VICL Guru Trades in Q1 2014

Murray Stahl 84,500 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
John Rogers 5,795,085 sh (-17.94%)
» More
Q2 2014

VICL Guru Trades in Q2 2014

George Soros 58,179 sh (New)
John Rogers 5,795,210 sh (unchged)
Murray Stahl 84,500 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with VICL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 New Buy$1.12 - $1.35 $ 1.18-1%58179
John Burbank 2012-12-31 Sold Out 0.05%$2.74 - $4.32 $ 1.18-64%0
John Burbank 2012-09-30 New Buy0.05%$3.3 - $4.58 $ 1.18-68%250000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.80
VICL's P/B is ranked higher than
92% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. VICL: 1.80 )
VICL' s 10-Year P/B Range
Min: 0.79   Max: 7.65
Current: 1.8

0.79
7.65
P/S 8.40
VICL's P/S is ranked higher than
82% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 20.67 vs. VICL: 8.40 )
VICL' s 10-Year P/S Range
Min: 5.19   Max: 52
Current: 8.4

5.19
52
EV-to-EBIT -2.84
VICL's EV-to-EBIT is ranked higher than
50% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. VICL: -2.84 )
VICL' s 10-Year EV-to-EBIT Range
Min: 118   Max: 267
Current: -2.84

118
267
Current Ratio 14.26
VICL's Current Ratio is ranked higher than
93% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. VICL: 14.26 )
VICL' s 10-Year Current Ratio Range
Min: 3.91   Max: 38.92
Current: 14.26

3.91
38.92
Quick Ratio 14.26
VICL's Quick Ratio is ranked higher than
93% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. VICL: 14.26 )
VICL' s 10-Year Quick Ratio Range
Min: 3.91   Max: 38.92
Current: 14.26

3.91
38.92

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.53
VICL's Price/Net Cash is ranked higher than
96% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 190.00 vs. VICL: 2.53 )
VICL' s 10-Year Price/Net Cash Range
Min: 0.44   Max: 775
Current: 2.53

0.44
775
Price/Net Current Asset Value 2.33
VICL's Price/Net Current Asset Value is ranked higher than
97% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 79.32 vs. VICL: 2.33 )
VICL' s 10-Year Price/Net Current Asset Value Range
Min: 0.43   Max: 275
Current: 2.33

0.43
275
Price/Tangible Book 1.92
VICL's Price/Tangible Book is ranked higher than
94% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9.62 vs. VICL: 1.92 )
VICL' s 10-Year Price/Tangible Book Range
Min: 0.4   Max: 13.37
Current: 1.92

0.4
13.37
Price/Median PS Value 0.68
VICL's Price/Median PS Value is ranked higher than
93% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. VICL: 0.68 )
VICL' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 5.23
Current: 0.68

0.32
5.23
Earnings Yield (Greenblatt) 1.60
VICL's Earnings Yield (Greenblatt) is ranked higher than
59% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. VICL: 1.60 )
VICL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 0.8
Current: 1.6

0.4
0.8
Forward Rate of Return (Yacktman) -25.21
VICL's Forward Rate of Return (Yacktman) is ranked higher than
67% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. VICL: -25.21 )
VICL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -19.9   Max: -15.2
Current: -25.21

-19.9
-15.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:VCC.Germany
Vical Incorporated, a Delaware corporation, was incorporated in April 1987 and has devoted all of its resources since that time to its research and development programs. The Company researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The Company currently has five active independent clinical and preclinical development programs in the areas of infectious disease and cancer including: A fully enrolled Phase 3 clinical trial using its Allovectin-7(r) immunotherapeutic in patients with metastatic melanoma which has been funded, up to certain limits, by AnGes MG, Inc., or AnGes, through cash payments and equity investments under a research and development agreement; A fully enrolled Phase 2 clinical trial using TransVax(tm), its cytomegalovirus, or CMV, therapeutic DNA vaccine, in patients undergoing hematopoietic cell transplants; Completed Phase 1 clinical trials using H5N1 pandemic influenza DNA vaccine formulated with its proprietary Vaxfectin(r) adjuvant; A preclinical program using H1N1 pandemic influenza DNA vaccine formulated with proprietary Vaxfectin(r) adjuvant; and A preclinical program using CyMVectin(tm) prophylactic vaccine formulated with the proprietary Vaxfectin(r) adjuvant to prevent CMV infection before and during pregnancy to preclude fetal transmission. The Company is subject to various federal, state and local laws, regulations, and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its research.
» More Articles for VICL

Headlines

Articles On GuruFocus.com
John Rogers Comments on Vical Feb 26 2014 
Kids Decide on Dolls or Devices - JAKK, Others 70% Off Sep 17 2013 
comment on VICL Mar 02 2013 
Weekly CFO Buys Highlight: VICL, EXA, UCBA, YORW, MGI Jan 21 2013 
Vical Inc. Insiders Boost Shares after Company’s NASDAQ Listing Gets Upgrade Jan 17 2013 
Two Biotech Stocks to Buy, One to Avoid Jan 09 2012 
Vical Inc. (VICL) CEO Vijay B Samant buys 1,000 Shares Jan 20 2011 
Vical Inc. Reports Operating Results (10-Q) Aug 06 2010 
Vical Inc. Reports Operating Results (10-Q) May 07 2010 
creiter note on VICL Jan 03 2010 

More From Other Websites
Vical to Present at the Rodman and Renshaw 16th Annual Global Investment Conference Sep 04 2014
VICAL INC Financials Aug 08 2014
VICAL INC Files SEC form 10-Q, Quarterly Report Aug 01 2014
VICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jul 31 2014
Vical Reports Second Quarter 2014 Financial Results and Progress in Key Development Programs Jul 31 2014
Vical Announces News Release and Conference Call Schedule for Second Quarter 2014 Financial Results Jul 24 2014
Vical to Present at the JMP Securities Annual Healthcare Conference Jun 18 2014
VICAL INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 28 2014
Earnings Estimates Moving Higher for Vical (VICL): Time to Buy? May 15 2014
Vical Narrows Q1 Loss May 06 2014
VICAL INC Files SEC form 10-Q, Quarterly Report May 02 2014
Vical's CEO Discusses Q1 2014 Results - Earnings Call Transcript May 01 2014
VICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 01 2014
VICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... Apr 15 2014
3 Stocks Under $10 Moving Higher Mar 21 2014
Why Vical (VICL) Might Be a Diamond in the Rough? Mar 12 2014
VICAL INC Files SEC form 10-K, Annual Report Feb 14 2014
Vical Q4 Loss Narrows Feb 13 2014
Vical's CEO Discusses Q4 2013 Results - Earnings Call Transcript Feb 12 2014
VICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 12 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK